Pharmaceutical composition containing nitroquinoline lysine salt, preparation method and use thereof

By developing a bilayer structure of nitric hydroxyquinoline lysine drug composition, the problem of insufficient water solubility of nitric hydroxyquinoline is solved, the sudden and slow release of drugs is achieved, and its drug properties and clinical application are improved prospect.

CN115768411BActive Publication Date: 2024-12-03JIANGSU YAHONG MEDITECH CO LTD +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202180047477.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-07-03
Filing Date
2021-05-26
Publication Date
2024-12-03
Estimated Expiration
2041-05-26

AI Technical Summary

Technical Problem

In the prior art, nitric hydroxyquinoline is insufficient in water solubility, which affects its drug properties and activity performance, and lacks pharmaceutical composition preparations containing nitric hydroxyquinoline lysine salt.

Method used

A pharmaceutical composition containing nitrohydroxyquinoline lysine was developed, adopting a two-layer structure design, the first and second layers each contain 40%-70% of the active pharmaceutical ingredients, combined with an appropriate amount of filler, The detoxifier, lubricant, glidant and sustained-release materials are prepared by wet granulation and tableting technology to achieve the effects of sudden and slow-release drugs.

Benefits of technology

It improves the dissolution properties and pharmacokinetic characteristics of the drug, achieves the purpose of early sudden release and late slow release drugs, and has good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GPA0000334571100000021
    Figure GPA0000334571100000021
  • Figure GPA0000334571100000061
    Figure GPA0000334571100000061
  • Figure GPA0000334571100000062
    Figure GPA0000334571100000062
Patent Text Reader

Abstract

A pharmaceutical composition containing nitroquinoline lysine salt, a preparation method thereof and uses thereof. The pharmaceutical composition comprises a first layer and a second layer, wherein the first layer comprises 40%-70% of an active pharmaceutical ingredient, 10%-30% of a filler, 5%-12% of a disintegrant, 0.5%-2% of a lubricant, 0.1%-1.5% of a glidant and 10%-20% of an alkaline substance based on the total weight of the first layer; the second layer comprises 40%-70% of an active pharmaceutical ingredient, 10%-30% of a filler, 10%-35% of a sustained-release material, 0.1%-2% of a lubricant and 0.1%-2% of a glidant based on the total weight of the second layer; the active pharmaceutical ingredient is selected from one or more of nitroquinoline lysine salt, nitroquinoline lysine salt crystal form and nitroquinoline lysine salt solvate. The pharmaceutical composition can achieve the purpose of early burst release and later sustained slow release of the drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a pharmaceutical composition containing nitroquinoline lysine salt, a preparation method and application thereof. Background Art

[0002] Nitroxoline, whose chemical name is 5-nitro-8-hydroxyquinoline, was developed as an oral antibiotic in the 1960s. It was mainly used for urinary tract infections and had a relatively safe use history. It was later replaced by the discovery and use of new antibiotics.

[0003] In recent years, new studies have found that nitroquinoline can simultaneously inhibit the methionine aminopeptidase MetAP2 and the silent information regulator 2-related enzyme SIRT1 in vascular endothelial cells, exerting a synergistic inhibitory effect on tumor angiogenesis, while also inhibiting the proliferation of tumor cells. Therefore, nitroquinoline has been redeveloped for the treatment of tumors including bladder cancer.

[0004] However, how to improve the water solubility of nitroquinoline, thereby contributing to its drugability and activity, is a problem that needs to be solved in the art.

[0005] Example 18 of the patent application with publication number CN 105228984 A and publication date 2016.01.06 discloses a nitroquinoline lysine salt and a preparation method thereof, wherein the water solubility of the nitroquinoline lysine salt is better than that of nitroquinoline. However, in the prior art, there is no pharmaceutical composition, such as a preparation, containing the nitroquinoline lysine salt. Summary of the invention

[0006] The inventors have developed a pharmaceutical composition for nitroquinoline lysine salt through intensive research, and the pharmaceutical composition has good dissolution properties and can achieve the purpose of early burst release and later continuous slow release.

[0007] Therefore, the present invention provides a pharmaceutical composition containing nitroquinoline lysine salt, which comprises a first layer and a second layer;

[0008] The first layer comprises 40%-70% of active pharmaceutical ingredients, 10%-30% of fillers, 5%-12% of disintegrants, 0.5%-2% of lubricants, 0.1%-1.5% of glidants and 10%-20% of alkaline substances based on the total weight of the first layer; the second layer comprises 40%-70% of active pharmaceutical ingredients, 10%-30% of fillers, 10%-35% of sustained-release materials, 0.1%-2% of lubricants and 0.1%-2% of glidants based on the total weight of the second layer; the active pharmaceutical ingredients in the first layer and the second layer are independently selected from one or more of nitroquinoline lysine salt, crystalline forms of nitroquinoline lysine salt and nitroquinoline lysine salt solvates.

[0009] In the above-mentioned pharmaceutical composition, the structural formula of the nitrohydroxyquinoline lysine salt is as follows:

[0010]

[0011] In the above-mentioned pharmaceutical composition, the active pharmaceutical ingredient is preferably a solvate of nitroquinoline lysine salt, more preferably a hydrate of nitroquinoline lysine salt, and further more preferably a monohydrate of nitroquinoline lysine salt, whose structural formula is It can be prepared by the preparation method of Example 18 of the patent application with publication number CN 105228984 A and publication date 2016.01.06.

[0012] In the above pharmaceutical composition, the mass percentage of the active pharmaceutical ingredient in the first layer in the first layer is preferably 40%-60%, more preferably 55%-57%, and most preferably 56%.

[0013] In the above pharmaceutical composition, the filler in the first layer may be one or more of microcrystalline cellulose, starch, lactose monohydrate and calcium hydrogen phosphate, preferably microcrystalline cellulose or starch, more preferably microcrystalline cellulose.

[0014] In the above pharmaceutical composition, the mass percentage of the filler in the first layer is preferably 15%-30%, more preferably 19%-20%, and most preferably 19.5%.

[0015] In the above pharmaceutical composition, the disintegrant in the first layer may be one or more of crospovidone, sodium starch glycolate, low-substituted hydroxypropyl cellulose and crospovidone sodium, preferably crospovidone or sodium starch glycolate, and more preferably crospovidone.

[0016] In the above pharmaceutical composition, the mass percentage of the disintegrant in the first layer is preferably 7%-12%, more preferably 7.5%-8.5%, and most preferably 8%.

[0017] In the above pharmaceutical composition, the lubricant in the first layer may be one or more of magnesium stearate, stearic acid and sodium lauryl sulfate, preferably magnesium stearate or stearic acid, more preferably magnesium stearate.

[0018] In the above pharmaceutical composition, the mass percentage of the lubricant in the first layer is preferably 0.5%-1.5%, most preferably 1%.

[0019] In the above pharmaceutical composition, the glidant in the first layer may be one or both of micro-powder silica gel and talcum powder, preferably micro-powder silica gel.

[0020] In the above pharmaceutical composition, the mass percentage of the glidant in the first layer is preferably 0.2%-1%, most preferably 0.5%.

[0021] In the above pharmaceutical composition, the alkaline substance in the first layer may be one or both of sodium bicarbonate and sodium carbonate, preferably sodium bicarbonate.

[0022] In the above pharmaceutical composition, the mass percentage of the alkaline substance in the first layer is preferably 14%-20%, more preferably 14%-16%, and most preferably 15%.

[0023] In the above pharmaceutical composition, the mass percentage of the active pharmaceutical ingredient in the second layer is preferably 50%-60%, more preferably 55%-57%, and most preferably 56%.

[0024] In the above pharmaceutical composition, the filler in the second layer may be one or more of microcrystalline cellulose, starch, lactose monohydrate and calcium hydrogen phosphate, preferably lactose monohydrate or microcrystalline cellulose, more preferably lactose monohydrate.

[0025] In the above pharmaceutical composition, the mass percentage of the filler in the second layer is preferably 16%-30%, more preferably 17%-19%, and most preferably 18%.

[0026] In the above pharmaceutical composition, the sustained-release material in the second layer may be one or both of hydroxypropyl methylcellulose and xanthan gum, preferably hydroxypropyl methylcellulose, more preferably one or more of hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose K15M and hydroxypropyl methylcellulose K100M, and further more preferably hydroxypropyl methylcellulose K4M.

[0027] In the above pharmaceutical composition, the mass percentage of the sustained-release material in the second layer is preferably 19%-35%, more preferably 24%-26%, and most preferably 25%.

[0028] In the above pharmaceutical composition, the lubricant in the second layer may be one or more of magnesium stearate, stearic acid and sodium lauryl sulfate, preferably magnesium stearate or stearic acid, more preferably magnesium stearate.

[0029] In the above pharmaceutical composition, the mass percentage of the lubricant in the second layer is preferably 0.2%-1%, most preferably 0.5%.

[0030] In the above pharmaceutical composition, the glidant in the second layer may be one or both of micro-powder silica gel and talcum powder, preferably micro-powder silica gel.

[0031] In the above pharmaceutical composition, the mass percentage of the glidant in the second layer is preferably 0.2%-1%, most preferably 0.5%.

[0032] In the above pharmaceutical composition, the mass ratio of the first layer to the second layer is preferably 1:3-2:1, more preferably 1:2-1:1.5, and most preferably 1:2. The mass ratio of the first layer to the second layer can make the obtained pharmaceutical composition have good pharmacokinetic characteristics, can be advantageously used in the preparation of drugs, and has good clinical application prospects.

[0033] In the above-mentioned pharmaceutical composition, the pharmaceutical composition may further comprise a coating agent. The type of the coating agent may be the type of coating agent conventionally used in the art, such as a coating agent with a trade name of Opadry. The amount of the coating agent may be the conventional amount in the art, such as a ratio of the mass of the coating agent to the mass of the pharmaceutical composition before coating of 2% to 4%.

[0034] In the above pharmaceutical composition, the pharmaceutical composition may further comprise one or more of a colorant, a pH adjuster, a surfactant, a stabilizer and a fragrance.

[0035] The pharmaceutical composition of the present invention may be in a conventional dosage form in the art, such as a solid preparation, for example, granules, powders or tablets, preferably tablets, more preferably sustained-release tablets, such as oral tablets or oral sustained-release tablets.

[0036] The present invention also provides a preparation containing nitroquinoline lysine salt, the preparation comprising a first layer and a second layer, the first layer comprising, based on the total weight of the first layer, 40%-70% of an active pharmaceutical ingredient, 10%-30% of a filler, 5%-12% of a disintegrant, 0.5%-2% of a lubricant, 0.1%-1.5% of a glidant and 10%-20% of an alkaline substance; the second layer comprising, based on the total weight of the second layer, 40%-70% of an active pharmaceutical ingredient, 10%-30% of a filler, 10%-35% of a sustained-release material, 0.1%-2% of a lubricant and 0.1%-2% of a glidant; the active pharmaceutical ingredients in the first layer and the second layer are each independently selected from one or more of nitroquinoline lysine salt, a crystal form of nitroquinoline lysine salt and a solvate of nitroquinoline lysine salt, preferably a hydrate of nitroquinoline lysine salt, more preferably nitroquinoline lysine salt monohydrate;

[0037] In the first layer, the filler is one or more of microcrystalline cellulose, starch, lactose monohydrate and calcium hydrogen phosphate, the disintegrant is one or more of cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose and cross-linked sodium carboxymethyl cellulose, the lubricant is one or more of magnesium stearate, stearic acid and sodium lauryl sulfate, the glidant is one or both of micro-powdered silica gel and talc, and the alkaline substance is one or both of sodium bicarbonate and sodium carbonate;

[0038] In the second layer, the filler is one or more of lactose monohydrate, microcrystalline cellulose, starch and calcium hydrogen phosphate, the sustained-release material is one or both of hydroxypropyl methylcellulose and xanthan gum, the lubricant is one or more of magnesium stearate, stearic acid and sodium lauryl sulfate, and the glidant is one or both of micro-powdered silica gel and talc.

[0039] Among the above preparations, the preparation is preferably a tablet, more preferably a sustained-release tablet.

[0040] In the above preparation, preferably, in the first layer, the filler is microcrystalline cellulose, the disintegrant is cross-linked polyvinylpyrrolidone, the lubricant is magnesium stearate, the glidant is micro-powdered silica gel, and the alkaline substance is sodium bicarbonate; in the second layer, the filler is lactose monohydrate, the sustained-release material is hydroxypropyl methylcellulose K4M, the lubricant is magnesium stearate, and the glidant is micro-powdered silica gel. More preferably, the mass ratio of the first layer to the second layer is 1:3-2:1, preferably 1:2-1:1.5, more preferably 1:2. The types of substances in the first and second layers and the mass ratio of the first and second layers can make the resulting preparation have better pharmacokinetic characteristics, can be more advantageously used in the preparation of drugs, and have better clinical application prospects.

[0041] The present invention also provides a method for preparing the aforementioned pharmaceutical composition containing nitroquinoline lysine salt, which comprises the following steps:

[0042] 1) mixing the remaining components of the first layer except the lubricant and the glidant, and wet granulating to obtain granules I; mixing the granules I with the lubricant and the glidant in the first layer to obtain first-layer granules;

[0043] 2) mixing the remaining components of the second layer except the lubricant and the glidant, and wet granulating to obtain Granules II; mixing the Granules II with the lubricant and the glidant in the second layer to obtain second-layer granules;

[0044] 3) The first layer of particles are tableted to obtain the first layer; the second layer of particles are tableted on top of the first layer to obtain; or, the second layer of particles are tableted to obtain the second layer; the first layer of particles are tableted on top of the second layer to obtain.

[0045] In the above preparation method, the wet granulation can refer to the conventional art, generally, the remaining components of the first layer or the second layer except the lubricant and the glidant are mixed with the ethanol aqueous solution to prepare a soft material, sieve, dry, and granulate. The mass fraction of the ethanol aqueous solution is preferably 70wt%-80wt%, for example 75wt%.

[0046] The present invention further provides a use of the aforementioned pharmaceutical composition containing nitroxyquinoline lysine salt or the preparation containing nitroxyquinoline lysine salt in the preparation of a drug for treating infectious diseases or cancer. The infectious disease is preferably urinary tract infection. The cancer is preferably bladder cancer.

[0047] The pharmaceutical composition of the present invention can be administered to mammals, preferably humans, twice a day, 2 tablets each time, at a dosage of 280 mg per tablet (equivalent to 150 mg of nitroquinol).

[0048] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0049] The reagents and raw materials used in the present invention are commercially available.

[0050] The positive improvement effect of the present invention is that the pharmaceutical composition of the present invention has good dissolution properties; through the combination of drug release characteristics in different layers, it can achieve the purpose of a burst release of drugs in the early stage (within 0-2 hours) and continuous slow release of drugs in the later stage (2-12 hours). BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 The release curves of the tablets prepared in Examples 1-3 in PBS at pH 6.8.

[0052] Figure 2 The release curves of the tablets prepared in Examples 1-3 in water are shown below.

[0053] Figure 3 The release curves of the tablets prepared in Examples 4-8 in water are shown below. DETAILED DESCRIPTION

[0054] The present invention will be described in more detail below in conjunction with embodiments. The embodiments of the present invention are only used to illustrate the technical solutions of the present invention, and are not intended to limit the essence and scope of the present invention.

[0055] In the following embodiments, the active pharmaceutical ingredient refers to nitroquinoline lysine salt monohydrate, whose chemical name is 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, and whose structural formula is:

[0056]

[0057] In the following examples, the experimental reagents are as follows:

[0058]

[0059] In the following embodiments, the components and contents in the first layer and the second layer are as follows:

[0060]

[0061]

[0062] In the following examples, the tablet press is a TDP-6 single punch tablet press manufactured by Shanghai Tianfan Pharmaceutical Machinery Manufacturing Co., Ltd.

[0063] Example 1

[0064] The active pharmaceutical ingredient and each excipient are sieved through an 80-mesh sieve for later use.

[0065] According to the above first-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, microcrystalline cellulose, cross-linked polyvinylpyrrolidone and sodium bicarbonate are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the first-layer prescription) to prepare a soft material, pass through a 24-mesh sieve, dry in a blast drying oven at 60°C for 2 hours, and then sieve through a 24-mesh sieve to size the particles, and then add magnesium stearate and micro-powdered silica gel, mix well, and the first-layer particles are obtained.

[0066] According to the above second-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, lactose monohydrate and hydroxypropyl methylcellulose K4M are fully mixed, and then a 75wt% ethanol aqueous solution (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the second-layer prescription) is used to prepare a soft material, which is sieved through a 24-mesh sieve and dried in a blast drying oven at 60°C for 2 hours. Then, the granules are sieved through a 24-mesh sieve, and magnesium stearate and micro-powder silica gel are added and mixed to obtain the second-layer granules.

[0067] Weigh 250 mg of the first layer granules and the second layer granules for use (i.e., the mass ratio of the two is 1:1). Pour the first layer granules into the die ring of the tablet press, and gently press them flat to form the first layer. Then pour the second layer granules into the die ring of the tablet press, and press the second layer on top of the first layer to obtain the tablet of Example 1. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80N.

[0068] Example 2

[0069] The first layer particles and the second layer particles were prepared according to the method of Example 1.

[0070] Weigh 166.67 mg of the first layer granules and 333.33 mg of the second layer granules for later use (i.e., the mass ratio of the two is 1:2). Pour the second layer granules into the die ring of the tablet press, and gently press them flat to form the second layer. Pour the first layer granules into the die ring of the tablet press again, and press the first layer on top of the second layer to obtain the tablet of Example 2. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80 N.

[0071] Example 3

[0072] The first layer particles and the second layer particles were prepared according to the method of Example 1.

[0073] Weigh 333.33 mg of the first layer granules and 166.67 mg of the second layer granules for later use (i.e., the mass ratio of the two is 2:1). Pour the first layer granules into the die ring of the tablet press, press them lightly to make them flat, and use them as the first layer; then pour the second layer granules into the die ring of the tablet press, and press the second layer on top of the first layer to obtain the tablets of Example 3. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80 N.

[0074] Example 4

[0075] The active pharmaceutical ingredient and each excipient are sieved through an 80-mesh sieve for later use.

[0076] According to the above first-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, microcrystalline cellulose, cross-linked polyvinylpyrrolidone and sodium bicarbonate are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the first-layer prescription) to prepare a soft material, pass through a 24-mesh sieve, dry in a blast drying oven at 60°C for 2 hours, and then sieve through a 24-mesh sieve to size the particles, and then add magnesium stearate and micro-powdered silica gel, mix well, and the first-layer particles are obtained.

[0077] According to the above second-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, lactose monohydrate and hydroxypropyl methylcellulose K4M are fully mixed, and then a 75wt% ethanol aqueous solution (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the second-layer prescription) is used to prepare a soft material, which is sieved through a 24-mesh sieve and dried in a blast drying oven at 60°C for 2 hours. Then, the granules are sieved through a 24-mesh sieve, and magnesium stearate and micro-powder silica gel are added and mixed to obtain the second-layer granules.

[0078] Weigh 166.67 mg of the first layer granules and 333.33 mg of the second layer granules for later use (i.e., the mass ratio of the two is 1:2). Pour the second layer granules into the die ring of the tablet press, and gently press them flat to form the second layer. Pour the first layer granules into the die ring of the tablet press again, and press the first layer on top of the second layer to obtain the tablet of Example 4. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80 N.

[0079] Example 5

[0080] The active pharmaceutical ingredient and each excipient are sieved through an 80-mesh sieve for later use.

[0081] According to the above first-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, microcrystalline cellulose, cross-linked polyvinylpyrrolidone and sodium bicarbonate are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the first-layer prescription) to prepare a soft material, pass through a 24-mesh sieve, dry in a blast drying oven at 60°C for 2 hours, and then sieve through a 24-mesh sieve to size the particles, and then add magnesium stearate and micro-powdered silica gel, mix well, and the first-layer particles are obtained.

[0082] According to the above second-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, lactose monohydrate and hydroxypropyl methylcellulose K4M are fully mixed, and then a 75wt% ethanol aqueous solution (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the second-layer prescription) is used to prepare a soft material, which is sieved through a 24-mesh sieve and dried in a blast drying oven at 60°C for 2 hours. Then, the granules are sieved through a 24-mesh sieve, and magnesium stearate and micro-powder silica gel are added and mixed to obtain the second-layer granules.

[0083] Weigh 333.33 mg of the first layer granules and 166.67 mg of the second layer granules for later use (i.e., the mass ratio of the two is 2:1). Pour the first layer granules into the die ring of the tablet press, press them lightly to make them flat, and use them as the first layer; then pour the second layer granules into the die ring of the tablet press, and press the second layer on top of the first layer to obtain the tablets of Example 5. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80 N.

[0084] Example 6

[0085] The active pharmaceutical ingredient and each excipient are sieved through an 80-mesh sieve for later use.

[0086] According to the above first-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, lactose monohydrate, low-substituted hydroxypropyl cellulose and sodium carbonate are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the first-layer prescription) to prepare a soft material, pass through a 24-mesh sieve, dry in a blast drying oven at 60°C for 2 hours, and then sieve through a 24-mesh sieve to size the particles, and then add sodium lauryl sulfate and talcum powder, mix well, and the first-layer particles are obtained.

[0087] According to the above second-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, microcrystalline cellulose and xanthan gum are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is conventional, and its mass accounts for 10%-30% of the total material mass of the second-layer prescription) to prepare a soft material, pass through a 24-mesh sieve, dry in a blast drying oven at 60°C for 2 hours, and then sieve through a 24-mesh sieve to size the particles, and then add stearic acid and talc and mix well to obtain the second-layer particles.

[0088] Weigh 250 mg of the first layer granules and 250 mg of the second layer granules for later use (i.e., the mass ratio of the two is 1:1). Pour the first layer granules into the die ring of the tablet press, and gently press them flat to form the first layer; then pour the second layer granules into the die ring of the tablet press, and press the second layer on top of the first layer to obtain the tablets of Example 6. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80N.

[0089] Example 7

[0090] The active pharmaceutical ingredient and each excipient are sieved through an 80-mesh sieve for later use.

[0091] According to the above first-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, starch, sodium carboxymethyl starch and sodium carbonate are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the first-layer prescription) to prepare a soft material, which is sieved through a 24-mesh sieve and dried in a blast drying oven at 60°C for 2 hours. Then, the granules are sieved through a 24-mesh sieve, and stearic acid and talc are added and mixed to obtain the first-layer granules.

[0092] According to the above second-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, starch and xanthan gum are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is conventional, and its mass accounts for 10%-30% of the total material mass of the second-layer prescription) to prepare a soft material, pass through a 24-mesh sieve, dry in a blast drying oven at 60°C for 2 hours, and then sieve through a 24-mesh sieve to size the particles, and then add sodium lauryl sulfate and talcum powder and mix well to obtain the second-layer particles.

[0093] Weigh 250 mg of the first layer granules and 250 mg of the second layer granules for later use (i.e., the mass ratio of the two is 1:1). Pour the first layer granules into the die ring of the tablet press, and gently press them flat to form the first layer; then pour the second layer granules into the die ring of the tablet press, and press the second layer on top of the first layer to obtain the tablets of Example 7. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80N.

[0094] Example 8

[0095] The active pharmaceutical ingredient and each excipient are sieved through an 80-mesh sieve for later use.

[0096] According to the above first-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, calcium hydrogen phosphate, cross-linked carboxymethyl cellulose sodium and sodium bicarbonate are fully mixed, and then a 75wt% ethanol aqueous solution (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the first-layer prescription) is used to prepare a soft material, which is sieved through a 24-mesh sieve and dried in a blast drying oven at 60°C for 2 hours. Then, the granules are sieved through a 24-mesh sieve, and magnesium stearate and micro-powdered silica gel are added and mixed to obtain the first-layer granules.

[0097] According to the above second-layer prescription, each component is accurately weighed, 5-nitro-8-hydroxyquinoline L-lysine salt monohydrate, calcium hydrogen phosphate and hydroxypropyl methylcellulose K4M are fully mixed, and then a 75wt% ethanol aqueous solution is used (the amount of 75wt% ethanol aqueous solution is a conventional amount, and its mass accounts for 10%-30% of the total mass of the second-layer prescription) to prepare a soft material, pass through a 24-mesh sieve, dry in a blast drying oven at 60°C for 2 hours, and then sieve through a 24-mesh sieve to size the particles, and then add magnesium stearate and micro-powder silica gel, mix well, and the second-layer particles are obtained.

[0098] Weigh 250 mg of the first layer granules and 250 mg of the second layer granules for later use (i.e., the mass ratio of the two is 1:1). Pour the first layer granules into the die ring of the tablet press, press them lightly to make them flat, and use them as the first layer; then pour the second layer granules into the die ring of the tablet press, and press the second layer on top of the first layer to obtain the tablets of Example 8. The diameter of the tablet press punch is 11 mm, and the pressure is controlled at 60-80 N.

[0099] Test Example 1 Release

[0100] (1) Selection of release medium

[0101] Since the solubility of the main drug (5-nitro-8-hydroxyquinoline L-lysine salt monohydrate) is greatly affected by pH, in order to select a suitable release medium to achieve the sink condition, the solubility of the main drug in water, hydrochloric acid solution with a pH of 1.0, buffer solution with a pH of 4.0 (liquid A: take 21g of citric acid or 19.2g of anhydrous citric acid, add water to dissolve it into 1000mL, and store it in a refrigerator. Liquid B: take 71.63g of disodium hydrogen phosphate, add water to dissolve it into 1000mL. Take 61.45mL of the above liquid A and 38.55mL of liquid B, mix them, shake well, and obtain) and PBS buffer solution with a pH of 6.8 (take 250mL of 0.2mol / L phosphoric acid solution , add 118mL of 0.2mol / L sodium hydroxide solution, dilute with water -1000mL, shake well, and get the saturated solubility in the above-mentioned medium. The specific method is to take an excess of the main drug (about 1.5g) in 10mL of the above four media, place it in a SHA-B multifunctional water bath constant temperature oscillator (manufacturer: Jiangsu Zhengji Instrument Co., Ltd.), the water bath temperature is 37°C, the oscillation speed is 280 rpm, shake it for 72h, take it out, filter it with a 0.45μm nitrocellulose membrane (manufacturer: Tianjin Jinteng Experimental Equipment Co., Ltd.), take the filtrate, and measure it with a UV-2700 ultraviolet-visible spectrophotometer (manufacturer: Shimadzu, Japan), and the detection wavelength is 369nm. The results are shown in Table 1 below.

[0102] Table 1 Saturated solubility of the main drug in different media

[0103] Media Type Saturated solubility (mg / ml) Whether the leakage condition is met water 100.5 yes Hydrochloric acid solution with a pH of 1.0 1.54 yes pH 4.0 buffer 0.43 no PBS buffer, pH 6.8 15.7 yes

[0104] The results showed that the sink condition could not be achieved in a buffer solution with a pH of 4.0, so hydrochloric acid solution with a pH of 1.0, water, and PBS buffer with a pH of 6.8 were selected as release media.

[0105] (2) Selection of release conditions

[0106] The release rate was determined with reference to the Chinese Pharmacopoeia basket method, with a rotation speed of 100 rpm. The release medium was PBS or water with a pH of 6.8, and the volume of the release medium was 900 mL at 37°C. One tablet in Example 1-3 was added to the dissolution cup respectively, 10 mL of the dissolution solution was absorbed within the time shown in Table 2 or 3 below, and then 10 mL of PBS or water with a pH of 6.8 at the same temperature was added, and the taken out dissolution solution was diluted by an appropriate multiple (10 or 20 times) (the data in Table 2 and Table 3 are generally diluted 10 times at the first time point and 20 times at subsequent time points), and its ultraviolet absorbance was measured, the release percentage was calculated, and the release curve was drawn, as shown in FIG. Figure 1 and 2 The release results are shown in Tables 2 and 3 below.

[0107] The release rate was determined with reference to the Chinese Pharmacopoeia basket method, with a rotation speed of 100 rpm. The release medium was water, with a release medium volume of 900 mL and a temperature of 37°C. A tablet in Example 4-8 was added to the dissolution cup, 10 mL of the dissolution solution was drawn within the time shown in Table 4 below, and then 10 mL of water at the same temperature was added. The taken-out dissolution solution was diluted by an appropriate multiple (10 or 20 times) (the data in Table 4 are generally diluted 10 times at the first time point and 20 times at subsequent time points), its ultraviolet absorbance was measured, the release percentage was calculated, and the release curve was drawn, as shown in FIG. Figure 3 The release results are shown in Table 4 below.

[0108] (3) Release test results

[0109] Table 2 Release results of the tablets of Examples 1-3 in PBS with a pH of 6.8

[0110] Tablet of Example 1 Average release rate (n=3) SD 0.5h 53.93% 1.53% 1h 59.15% 1.03% 2h 69.63% 2.30% 4h 79.46% 3.00% 6h 87.53% 2.22% 8h 93.71% 2.00% 10h 95.35% 2.16% 12h 97.58% 2.56% Tablet of Example 3 Average release rate (n=3) SD 0.5h 69.86% 2.36% 1h 79.31% 3.04% 2h 88.92% 2.84% 4h 95.89% 0.83% 6h 98.20% 0.11% 8h 100.00% 1.70% 10h 100.34% 1.93% 12h 101.84% 0.32% Tablet of Example 2 Average release rate (n=3) SD 0.5h 40.17% 2.31% 1h 44.41% 2.85% 2h 52.32% 2.33% 4h 65.76% 2.55% 6h 75.45% 1.30% 8h 87.77% 2.32% 10h 92.41% 2.36% 12h 96.99% 2.33%

[0111] Table 3 Release results of tablets of Examples 1-3 in water

[0112]

[0113]

[0114] Table 4 Release results of tablets of Examples 4-8 in water

[0115]

[0116]

[0117] According to Table 2-3 and Figure 1-2 The experimental results show that in water or PBS buffer with pH 6.8, the release curves of tablets with different mass ratios of the first layer to the second layer are different, and the tablet of Example 3 (the mass ratio of the first layer to the second layer is 2:1) has a release rate of 80% in 1 hour, the tablet of Example 1 (the mass ratio of the first layer to the second layer is 1:1) has a release rate of 80% in 4 hours, and the tablet of Example 2 (the mass ratio of the first layer to the second layer is 1:2) has a release rate of 80% in 8 hours. With the increase of the proportion of the first layer, the burst release in the early stage (0-2 hours) increases. From the release curve, it can be seen that in the early stage of release (0-2 hours), the burst release rate of the three is obvious, and the difference is significant, while in the later stage (2-8 hours), they all show a good sustained release effect, which is in line with the original intention of the design of the sustained-release double-layer tablet, and basically achieves the effect of combined sustained release and rapid release in vitro.

[0118] From Table 4 and Figure 3 It can be seen that the in vitro release curves of the tablets of Examples 4-8 are basically consistent with those of the tablets of Examples 1-3. In the early stage (within 0-2 hours), the first layer of drugs is rapidly released, which can achieve a rapid therapeutic effect; in the later stage (within 2-8 hours), the second layer of drugs is slowly released, which can maintain the therapeutic effect, which is in line with the original intention of the design of the sustained-release double-layer tablet, and basically achieves the effect of sustained-release and rapid-release combined drug release in vitro.

[0119] Test Example 2 Beagle dog pharmacokinetic test

[0120] Experimental design:

[0121] Select 3 qualified healthy beagle dogs (purchased from Beijing Mas Biotechnology Co., Ltd., 10-12 kg, 13-15 months), and orally administer the tablets prepared in Examples 1-3. The beagle dogs were fasted before the experiment and had free access to water. The experiment was conducted in 4 cycles, with one preparation given in each cycle, 1 tablet per beagle, and a recovery period of 2-3 days between each cycle. 2 mL of whole blood was collected from the front / hind limb vein at 0 min before administration, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 16 and 24 hours after administration, and placed in a 5 mL centrifuge tube containing EDTA-K2 anticoagulant (manufacturer: Guangzhou Bangbiao Medical Instrument Co., Ltd.), immediately mixed, and centrifuged at 5000 rpm for 5 minutes, 400 μL of plasma was quantitatively drawn, placed in another clean centrifuge tube, and placed in a -20°C refrigerator for testing.

[0122] Test sample: tablets prepared in Examples 1-3; reference preparation: 500 mg of the first layer of granules prepared in Example 1 was poured into the die of a tablet press, and tablets were pressed with a punch diameter of 11 mm and a pressure controlled at 60-80 N.

[0123] Sample testing:

[0124] Instruments: Agilent 1200 liquid chromatograph, AB SCIEX API4000 tandem quadrupole mass spectrometer

[0125] Acetonitrile, methanol, and formic acid were purchased from Dikma, and the remaining reagents were of chromatographic grade.

[0126] Liquid phase conditions:

[0127] Mobile phase: A: methanol-water-formic acid (10:90:0.1, v / v / v), B: methanol-formic acid (100:0.1, v / v)

[0128]

[0129] Flow rate: 0.40mL / min

[0130] Injection volume: 10 μL

[0131] Mass spectrometry conditions:

[0132] Ion source: Turbo Ionspray (ESI + );

[0133] Detection mode: MRM;

[0134] Ion source related parameters: GS1 (gas 1, psi): 50, GS2 (gas 2, psi): 50, TEM (temperature, ℃): 450, CUR (curtain gas, psi): 30, IS (spray voltage, V): 5000, CAD (collision gas, psi): 5, ihe (interface heater): on.

[0135] Table 5 Pharmacokinetic test results of the tablets of Examples 1-3

[0136]

[0137] As shown in Table 5 above, the tablets of Examples 1-3 and the reference preparation are bioequivalent in beagle dogs (F value range 80%-120%). max Lower than the reference preparation, can reduce the occurrence of side effects; while the blood drug concentration C of the tablet of Example 2 max Significantly reduced, half-life t 1 / 2 Significant delay and excellent sustained release effect.

Claims

1. A pharmaceutical composition containing nitroquinoline lysine salt, characterized in that: It comprises a first layer and a second layer; The first layer comprises, based on the total weight of the first layer, 40%-70% of an active pharmaceutical ingredient, 10%-30% of a filler, 5%-12% of a disintegrant, 0.5%-2% of a lubricant, 0.1%-1.5% of a glidant and 10%-20% of an alkaline substance, wherein the sum of the contents of each component is 100%; Wherein, the filler in the first layer is microcrystalline cellulose; the disintegrant in the first layer is cross-linked polyvinylpyrrolidone; the lubricant in the first layer is magnesium stearate; the glidant in the first layer is micro powder silica gel; the alkaline substance in the first layer is selected from one or both of sodium bicarbonate and sodium carbonate; The second layer comprises, based on the total weight of the second layer, 40%-70% of an active pharmaceutical ingredient, 10%-30% of a filler, 10%-35% of a sustained-release material, 0.1%-2% of a lubricant, and 0.1%-2% of a glidant, wherein the sum of the contents of each component is 100%; Wherein, the filler in the second layer is lactose monohydrate; the sustained-release material in the second layer is hydroxypropyl methylcellulose K4M; the lubricant in the second layer is magnesium stearate; and the glidant in the second layer is micro-powder silica gel; The active pharmaceutical ingredient in the first layer and the second layer is nitroquinoline lysine salt monohydrate; The mass ratio of the first layer to the second layer is 1:3-1:1.5; The pharmaceutical composition is a sustained-release tablet.

2. The pharmaceutical composition containing nitroquinoline lysine salt according to claim 1, characterized in that: The mass percentage of the active pharmaceutical ingredient in the first layer is 40%-60% in the first layer; The mass percentage of the filler in the first layer is 15%-30%; The mass percentage of the disintegrant in the first layer is 7%-12%; The mass percentage of the lubricant in the first layer is 0.5%-1.5%; The mass percentage of the glidant in the first layer is 0.2%-1%; The mass percentage of the alkaline substance in the first layer is 14%-20%.

3. The pharmaceutical composition containing nitroquinoline lysine salt according to claim 1, characterized in that: The mass percentage of the active pharmaceutical ingredient in the second layer is 50%-60%; The mass percentage of the filler in the second layer is 16%-30%; The mass percentage of the sustained-release material in the second layer is 19%-35%; The mass percentage of the lubricant in the second layer is 0.2%-1%; The mass percentage of the glidant in the second layer is 0.2%-1%.

4. The pharmaceutical composition containing nitroquinoline lysine salt according to claim 1, characterized in that: The mass ratio of the first layer to the second layer is 1:2-1:1.

5.

5. The pharmaceutical composition containing nitroquinoline lysine salt according to claim 1, characterized in that: The pharmaceutical composition further comprises a coating agent; The ratio of the mass of the coating agent to the mass of the pharmaceutical composition before coating is 2%-4%.

6. The pharmaceutical composition containing nitroquinoline lysine salt according to claim 1, characterized in that: The pharmaceutical composition further comprises one or more of a colorant, a pH adjuster, a surfactant, a stabilizer and a flavor.

7. A preparation containing nitroquinoline lysine salt, characterized in that: It includes a first layer and a second layer, The first layer comprises, based on the total weight of the first layer, 40% to 60% of an active pharmaceutical ingredient, 15% to 30% of a filler, 7% to 12% of a disintegrant, 0.5% to 1.5% of a lubricant, 0.2% to 1% of a glidant, and 14% to 20% of an alkaline substance; The second layer comprises, based on the total weight of the second layer, 50% to 60% of an active pharmaceutical ingredient, 16% to 30% of a filler, 19% to 35% of a sustained-release material, 0.2% to 1% of a lubricant, and 0.2% to 1% of a glidant; The preparation is a sustained-release tablet; In the first layer, the filler is microcrystalline cellulose, the disintegrant is cross-linked polyvinylpyrrolidone, the lubricant is magnesium stearate, the glidant is micro-powdered silica gel, and the alkaline substance is sodium bicarbonate; in the second layer, the filler is lactose monohydrate, the sustained-release material is hydroxypropyl methylcellulose K4M, the lubricant is magnesium stearate, and the glidant is micro-powdered silica gel; The mass ratio of the first layer to the second layer is 1:3-1:1.5; The active pharmaceutical ingredient in the first layer and the second layer is nitroquinoline lysine salt monohydrate.

8. The preparation containing nitroquinoline lysine salt according to claim 7, characterized in that The mass ratio of the first layer to the second layer is 1:2-1:1.

5.

9. A method for preparing a pharmaceutical composition containing nitroquinoline lysine salt according to any one of claims 1 to 6, characterized in that: It includes the following steps: 1) mixing the remaining components of the first layer except the lubricant and the glidant, and wet granulating to obtain granules I; mixing the granules I with the lubricant and the glidant in the first layer to obtain first-layer granules; 2) mixing the remaining components of the second layer except the lubricant and the glidant, and wet granulating to obtain Granules II; mixing the Granules II with the lubricant and the glidant in the second layer to obtain second-layer granules; 3) The first layer of particles are tableted to obtain the first layer; the second layer of particles are tableted on top of the first layer to obtain; or, the second layer of particles are tableted to obtain the second layer; the first layer of particles are tableted on top of the second layer to obtain.

10. Use of a pharmaceutical composition containing nitroquinoline lysine salt according to any one of claims 1 to 6 or a preparation containing nitroquinoline lysine salt according to any one of claims 7 to 8 in the preparation of a medicament for treating infectious diseases or cancer.

11. The use according to claim 10, characterized in that The infectious disease is urinary tract infection, and the cancer is bladder cancer.

Citation Information

Patent Citations

  • Base addition salts of nitroxoline and uses thereof

    CN105228984A

  • Pharmaceutical composition containing nitroxoline lysine salt as well as preparation method and application of the pharmaceutical composition

    CN111773193A

  • Antibacterial agent and method of its preparing

    RU2149632C1

  • Method for preparing antibacterial medicinal agent

    RU2224517C1